3BP company statement re recent events involving Clovis Oncology and FAP-2286

Company Statement Company statement re recent events involving Clovis Oncology and FAP-2286 Berlin, Germany, December 22, 2022 - In the context of a potential acquisition of Clovis Oncology's rights to FAP-2286 by Novartis under Section 363 of the US Bankruptcy Code, 3BP has consent to the Novartis purchase and 3BP and Novartis have agreed to enter into a license agreement with respect to 3BP's FAP-targeted peptide technology. The agreement between 3BP and Novartis is subject to the approval of the US Bankruptcy Court, and the closing of the purchase and assignment agreement between Clovis Oncology and Novartis in accordance with Section 363 of the Bankruptcy Code and expiration of the waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. About 3B Pharmaceuticals 3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development. Contact: 3B Pharmaceuticals GmbH Magnusstraße 11 D-12489 Berlin Tel: +49 (0)30 / 63 92 – 43 17 Fax: +49 (0)30 / 63 92 – 43 16 [email protected]

The release as fetched from its publisher. 3b-pharma.com ↗